Capmatinib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 49 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells by overexpressing the c-Met protein or expressing the constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindication in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells by overexpressing the c-Met protein or expressing the constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation – via mutations, amplification, and/or overexpression – is known to occur in many types of cancer and leads to the overactivation of multiple downstream signaling pathways such as STAT3, PI3K/ATK, and RAS/MAPK. Mutations in MET have been detected in non-small cell lung cancer (NSCLC), and the prevalence of MET amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-naive patients with NSCLC has been reported to be 1.4% – 21%. This co-occurrence has made c-Met a desirable target in the treatment of NSCLC. Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020, for the treatment of NSCLC in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same day. As this indication was granted under accelerated approval, its continued approval is contingent upon the verification of capmatinib’s benefit in confirmatory trials.

Capmatinib is a Kinase Inhibitor. The mechanism of action of capmatinib is as a Mesenchymal Epithelial Transition Inhibitor, Cytochrome P450 1A2 Inhibitor, and P-Glycoprotein Inhibitor, Breast Cancer Resistance Protein Inhibitor, Multidrug and Toxin Extrusion Transporter 1 Inhibitor, and Multidrug and Toxin Extrusion Transporter 2 K Inhibitor.

Capmatinib Hydrochloride is the hydrochloride salt form of capmatinib, an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells by overexpressing the c-Met protein or expressing the constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

Mechanism of Action

Aberrant activation of c-Met has been documented in many cancers, including non-small cell lung cancer (NSCLC). Mutations that result in the skipping of _MET_ exon 14 lead to the formation of a mutant c-Met with a missing regulatory domain – these mutant proteins have a reduced ability to negatively regulate, leading to a pathological increase in their downstream activity. Capmatinib inhibits the phosphorylation of both wild-type and mutant variants of c-Met triggered by the binding of its endogenous ligand, hepatocyte growth factor – in doing so, it prevents c-Met-mediated phosphorylation of downstream signaling proteins, as well as the proliferation and survival of c-Met-dependent tumor cells.

Capmatinib inhibits the overactivity of c-Met, a receptor tyrosine kinase encoded by the _MET_ proto-oncogene. Mutations in _MET_ are involved in the proliferation of many cancers, including non-small cell lung cancer (NSCLC). Capmatinib may cause photosensitivity reactions in patients following ultraviolet (UV) exposure – patients undergoing therapy with capmatinib should be advised to use sunscreen and protective clothing to limit exposure to UV radiation. Instances of interstitial lung disease/pneumonitis, which can be fatal, occurred in patients being treated with capmatinib. Patients presenting with signs or symptoms of lung disease (e.g. cough, dyspnea, fever) should have capmatinib immediately withheld, and capmatinib should be permanently discontinued if no other feasible causes of the lung-related symptoms are identified.

Indications

  • Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
  • Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
  • Capmatinib is a kinase inhibitor indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
  • In the US, capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
  • Capmatinib is approved to treat adults with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations in Canada.[rx]
  • Metastatic Non-Small Cell Lung Cancer
  • Unresectable, locally advanced Non-Small Cell Lung Carcinoma (NSCLC)

Use in Cancer

Capmatinib hydrochloride is approved to treat:

Capmatinib hydrochloride is also being studied in the treatment of other types of cancer.

Contraindication

  • abnormal liver function tests
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • lung tissue problem
  • pancreatitis

Dosage

Strengths: 150 mg; 200 mg

Non-Small Cell Lung Cancer

  • 400 mg orally 2 times daily
  • For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an approved test

Dose Adjustments

DOSE MODIFICATION RECOMMENDATIONS:

  • First dose reduction: 300 mg orally 2 times daily
  • Second dose reduction: 300 mg orally 2 times daily
  • Permanently discontinue this drug in patients who are unable to tolerate 200 mg orally 2 times daily.

DOSE MODIFICATION FOR ADVERSE REACTIONS:
INTERSTITIAL LUNG DISEASE (ILD)/PNEUMONITIS:

  • Any Grade: Permanently discontinue this drug.

Increased ALT and/or AST without increased total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin:

  • Grade 3: Withhold therapy until recovery to baseline ALT/AST; if recovered to baseline within 7 days, resume this drug at the same dose; otherwise resume at a reduced dose.
  • Grade 4: Permanently discontinue this drug.

INCREASED ALT AND/OR AST WITH INCREASED TOTAL jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">BILIRUBIN IN THE ABSENCE OF CHOLESTASIS OR HEMOLYSIS:

  • ALT and/or AST greater than 3 times the upper limit of normal (ULN) with total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin greater than 2 x ULN: Permanently discontinue this drug.

INCREASED TOTAL jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">BILIRUBIN WITHOUT CONCURRENT INCREASED ALT AND/OR AST:

  • Grade 2: Withhold therapy until recovery to baseline jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin; if recovered to baseline within 7 days, resume this drug at the same dose; otherwise resume at a reduced dose.
  • Grade 3: Withhold therapy until recovery to baseline jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin; if recovered to baseline within 7 days, resume this drug at a reduced dose; otherwise permanently discontinue this drug.
  • Grade 4: Permanently discontinue this drug.

OTHER ADVERSE REACTIONS:

  • Grade 2: Maintain dose level; if intolerable, consider withholding this drug until resolved, then resume at a reduced dose.
  • Grade 3: Withhold this drug until resolved then resume at a reduced dose.
  • Grade 4: Permanently discontinue this drug.

Side Effects

The Most Common

  • vomiting
  • nausea
  • diarrhea
  • constipation
  • muscle, bone, or pain: Back pain means pain in the spine, muscles, discs, joints, or nerves of the back. সহজ বাংলা: পিঠ/কোমরের ব্যথা।" data-rx-term="back pain" data-rx-definition="Back pain means pain in the spine, muscles, discs, joints, or nerves of the back. সহজ বাংলা: পিঠ/কোমরের ব্যথা।">back pain
  • loss of appetite
  • tiredness and weakness
  • dizziness
  • swelling in hands, feet, ankles, or lower legs
  • rash
  • shortness of breath or trouble breathing, cough, fever, or other signs of infection
  • chest pain
  • pain in right upper part of the stomach; swelling in your stomach area; unusual bruising or bleeding; dark urine; yellowing of the skin and eyes; nausea, vomiting; light-colored stools; loss of appetite
  • ongoing pain that begins in the stomach area, but may spread to the back; nausea; vomiting; weight loss

More Common

  • our skin or the white part of your eyes turns yellow
    (jaundice)
  • loss of appetite for several days or longer
  • dark or “tea-colored” urine o nausea and vomiting
  • light-colored stools (bowel movements)
  • confusion
  • pain, aching, or tenderness on the right side of your
  • stomach area (abdomen)
  • tiredness o weakness
  • swelling in your stomach-area

Rare

  • new or worsening cough, chest pain, trouble breathing;
  • fever, cough with mucus;
  • severe ongoing nausea and vomiting; or
  • signs of liver or pancreas problems–loss of appetite, upper stomach pain (that may spread to your back), nausea or vomiting, fast heart rate, dark urine, jaundice (yellowing of the skin or eyes).
  • trouble breathing;
  • vomiting decreased appetite;
  • feeling weak or tired
  • abnormal liver function tests;
  • swelling in your hands or feet.

Drug Interaction

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

Based on findings from animal studies and its mechanism of action, TABRECTA can cause fetal harm when administered to a pregnant woman. There are no available data on TABRECTA use in pregnant women. Oral administration of capmatinib to pregnant rats and rabbits during the period of organogenesis resulted in malformations at maternal exposures less than the human exposure based on AUC at the 400 mg twice daily clinical dose. Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Lactation

There are no data on the presence of capmatinib or its metabolites in either human or animal milk or its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with TABRECTA and for 1 week after the last dose.

How should this medicine be used?

Capmatinib comes as a tablet to take by mouth. It is usually taken twice daily with or without food. Take capmatinib at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take capmatinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the tablets whole; do not split, chew, or crush them.

If you vomit after taking capmatinib, do not take another dose. Continue your regular dosing schedule.

Your doctor may need to temporarily or permanently stop your treatment or decrease your dose of capmatinib during your treatment. This depends on how well the medication works for you and the side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with capmatinib.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

What special precautions should I follow?

Before taking capmatinib,

  • tell your doctor and pharmacist if you are allergic to capmatinib, any other medications, or any of the ingredients in capmatinib tablets. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • The following nonprescription or herbal products may interact with capmatinib: St. John’s Wort. Be sure to let your doctor and pharmacist know that you are taking these medications before you start taking capmatinib. Do not start any of these medications while taking capmatinib without discussing with your healthcare provider.
  • tell your doctor if you have or have ever had lung disease or breathing problems other than from lung cancer, pancreatitis (swelling of the pancreas), or liver disease.
  • tell your doctor if you are pregnant, or plan to become pregnant. You should not become pregnant while you are taking capmatinib. You will need to have a pregnancy test before you start treatment, and you should use birth control to prevent pregnancy during your treatment and for at least 1 week after your final dose. If you are a male with a female partner who may become pregnant, you should use birth control to prevent pregnancy during you treatment and for at least 1 week after your final dose. Capmatinib may harm your unborn baby. If you or your partner become pregnant during your treatment with capmatinib, call your doctor immediately.
  • tell your doctor if you are breastfeeding. You should not breastfeed while you are taking capmatinib and for at least 1 week after your final dose.
  • plan to avoid unnecessary or prolonged exposure to sunlight and to wear a hat, other protective clothing, sunglasses, and sunscreen.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Orthopedic / spine specialist, physical medicine doctor, or qualified clinician
Tests to discuss with doctor
  • Neurological examination for leg power, sensation, reflexes, and straight leg raise
  • X-ray only if injury, deformity, long-lasting pain, or doctor suspects bone problem
  • MRI discussion if severe nerve symptoms, weakness, bladder/bowel problem, or persistent symptoms
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Is physiotherapy, posture correction, or activity modification needed?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Capmatinib – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action Aberrant activation of c-Met has been documented in many cancers, including non-small cell lung cancer (NSCLC). Mutations that result in the skipping of _MET_ exon 14 lead to the formation of a mutant c-Met with a missing regulatory domain - these mutant proteins have a reduced ability to negatively regulate, leading to a pathological increase in their downstream activity. Capmatinib inhibits the phosphorylation of both wild-type and mutant variants of c-Met triggered by the binding of its endogenous ligand, hepatocyte growth factor - in doing so, it prevents c-Met-mediated phosphorylation of downstream signaling proteins, as well as the proliferation and survival of c-Met-dependent tumor cells. Capmatinib inhibits the overactivity of c-Met, a receptor tyrosine kinase encoded by the _MET_ proto-oncogene. Mutations in _MET_ are involved in the proliferation of many cancers, including non-small cell lung cancer (NSCLC). Capmatinib may cause photosensitivity reactions in patients following ultraviolet (UV) exposure - patients undergoing therapy with capmatinib should be advised to use sunscreen and protective clothing to limit exposure to UV radiation. Instances of interstitial lung disease/pneumonitis, which can be fatal, occurred in patients being treated with capmatinib. Patients presenting with signs or symptoms of lung disease (e.g. cough, dyspnea, fever) should have capmatinib immediately withheld, and capmatinib should be permanently discontinued if no other feasible causes of the lung-related symptoms are identified. Indications Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. Capmatinib is a kinase inhibitor indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. In the US, capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. Capmatinib is approved to treat adults with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations in Canada.[rx] Metastatic Non-Small Cell Lung Cancer Unresectable, locally advanced Non-Small Cell Lung Carcinoma (NSCLC) Use in Cancer Capmatinib hydrochloride is approved to treat: Non-small cell lung cancer has a certain mutation in the MET gene. It is used in adults whose cancer has spread to other parts of the body. Capmatinib hydrochloride is also being studied in the treatment of other types of cancer. Contraindication abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding lung tissue problem pancreatitis Dosage Strengths: 150 mg; 200 mg Non-Small Cell Lung Cancer 400 mg orally 2 times daily For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an approved test Dose Adjustments DOSE MODIFICATION RECOMMENDATIONS: First dose reduction: 300 mg orally 2 times daily Second dose reduction: 300 mg orally 2 times daily Permanently discontinue this drug in patients who are unable to tolerate 200 mg orally 2 times daily. DOSE MODIFICATION FOR ADVERSE REACTIONS: INTERSTITIAL LUNG DISEASE (ILD)/PNEUMONITIS: Any Grade: Permanently discontinue this drug. Increased ALT and/or AST without increased total bilirubin: Grade 3: Withhold therapy until recovery to baseline ALT/AST; if recovered to baseline within 7 days, resume this drug at the same dose; otherwise resume at a reduced dose. Grade 4: Permanently discontinue this drug. INCREASED ALT AND/OR AST WITH INCREASED TOTAL BILIRUBIN IN THE ABSENCE OF CHOLESTASIS OR HEMOLYSIS: ALT and/or AST greater than 3 times the upper limit of normal (ULN) with total bilirubin greater than 2 x ULN: Permanently discontinue this drug. INCREASED TOTAL BILIRUBIN WITHOUT CONCURRENT INCREASED ALT AND/OR AST: Grade 2: Withhold therapy until recovery to baseline bilirubin; if recovered to baseline within 7 days, resume this drug at the same dose; otherwise resume at a reduced dose. Grade 3: Withhold therapy until recovery to baseline bilirubin; if recovered to baseline within 7 days, resume this drug at a reduced dose; otherwise permanently discontinue this drug. Grade 4: Permanently discontinue this drug. OTHER ADVERSE REACTIONS: Grade 2: Maintain dose level; if intolerable, consider withholding this drug until resolved, then resume at a reduced dose. Grade 3: Withhold this drug until resolved then resume at a reduced dose. Grade 4: Permanently discontinue this drug. Side Effects The Most Common vomiting nausea diarrhea constipation muscle, bone, or back pain loss of appetite tiredness and weakness dizziness swelling in hands, feet, ankles, or lower legs rash shortness of breath or trouble breathing, cough, fever, or other signs of infection chest pain pain in right upper part of the stomach; swelling in your stomach area; unusual bruising or bleeding; dark urine; yellowing of the skin and eyes; nausea, vomiting; light-colored stools; loss of appetite ongoing pain that begins in the stomach area, but may spread to the back; nausea; vomiting; weight loss More Common our skin or the white part of your eyes turns yellow (jaundice) loss of appetite for several days or longer dark or “tea-colored” urine o nausea and vomiting light-colored stools (bowel movements) confusion pain, aching, or tenderness on the right side of your stomach area (abdomen) tiredness o weakness swelling in your stomach-area Rare new or worsening cough, chest pain, trouble breathing; fever, cough with mucus; severe ongoing nausea and vomiting; or signs of liver or pancreas problems--loss of appetite, upper stomach pain (that may spread to your back), nausea or vomiting, fast heart rate, dark urine, jaundice (yellowing of the skin or eyes). trouble breathing; vomiting decreased appetite; feeling weak or tired abnormal liver function tests; swelling in your hands or feet. Drug Interaction DRUG INTERACTION Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Capmatinib. Abametapir The serum concentration of Capmatinib can be increased when it is combined with Abametapir. Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Capmatinib. Acalabrutinib The serum concentration of Capmatinib can be increased when it is combined with Acalabrutinib. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Capmatinib. Acetaminophen The serum concentration of Capmatinib can be decreased when it is combined with Acetaminophen. Acyclovir The metabolism of Acyclovir can be decreased when combined with Capmatinib. Afatinib The serum concentration of Afatinib can be increased when it is combined with Capmatinib. Agomelatine The metabolism of Agomelatine can be decreased when combined with Capmatinib. Albendazole The metabolism of Albendazole can be decreased when combined with Capmatinib. Allopurinol The serum concentration of Allopurinol can be increased when it is combined with Capmatinib. Alosetron The metabolism of Alosetron can be decreased when combined with Capmatinib. Alpelisib The serum concentration of Capmatinib can be decreased when it is combined with Alpelisib. Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Capmatinib. Aminoglutethimide The serum concentration of Capmatinib can be decreased when it is combined with Aminoglutethimide. Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Capmatinib. Aminophylline The serum concentration of Aminophylline can be increased when it is combined with Capmatinib. Amiodarone The serum concentration of Capmatinib can be increased when it is combined with Amiodarone. Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Capmatinib. Amobarbital The serum concentration of Capmatinib can be decreased when it is combined with Amobarbital. Amprenavir The metabolism of Capmatinib can be decreased when combined with Amprenavir. Anagrelide The serum concentration of Anagrelide can be increased when it is combined with Capmatinib. Antipyrine The metabolism of Antipyrine can be decreased when combined with Capmatinib. Apalutamide The serum concentration of Capmatinib can be decreased when it is combined with Apalutamide. Apixaban The serum concentration of Apixaban can be increased when it is combined with Capmatinib. Apremilast The metabolism of Apremilast can be decreased when combined with Capmatinib. Aprepitant The metabolism of Capmatinib can be decreased when combined with Aprepitant. Armodafinil The serum concentration of Capmatinib can be decreased when it is combined with Armodafinil. Artemether The serum concentration of Capmatinib can be decreased when it is combined with Artemether. Articaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Articaine. Asenapine The metabolism of Asenapine can be decreased when combined with Capmatinib. Asunaprevir The serum concentration of Capmatinib can be decreased when it is combined with Asunaprevir. Atazanavir The serum concentration of Capmatinib can be increased when it is combined with Atazanavir. Avanafil The serum concentration of Avanafil can be increased when it is combined with Capmatinib. Avatrombopag The serum concentration of Avatrombopag can be increased when it is combined with Capmatinib. Axitinib The serum concentration of Axitinib can be increased when it is combined with Capmatinib. Azatadine The serum concentration of Capmatinib can be decreased when it is combined with Azatadine. Azathioprine The metabolism of Azathioprine can be decreased when combined with Capmatinib. Azelastine The metabolism of Azelastine can be decreased when combined with Capmatinib. Baricitinib The excretion of Baricitinib can be decreased when combined with Capmatinib. Beclomethasone The serum concentration of Capmatinib can be decreased when it is combined with Beclomethasone dipropionate. Belantamab mafodotin The serum concentration of Belantamab mafodotin can be increased when it is combined with Capmatinib. Belinostat The serum concentration of Belinostat can be increased when it is combined with Capmatinib. Bendamustine The serum concentration of Bendamustine can be increased when it is combined with Capmatinib. Benzocaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Benzyl alcohol. Berotralstat The serum concentration of Berotralstat can be increased when it is combined with Capmatinib. Betamethasone The serum concentration of Capmatinib can be decreased when it is combined with Betamethasone. Betaxolol The metabolism of Betaxolol can be decreased when combined with Capmatinib. Betrixaban The serum concentration of Betrixaban can be increased when it is combined with Capmatinib. Bexarotene The serum concentration of Capmatinib can be decreased when it is combined with Bexarotene. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Capmatinib. Bisoprolol The serum concentration of Bisoprolol can be increased when it is combined with Capmatinib. Boceprevir The metabolism of Capmatinib can be decreased when combined with Boceprevir. Bortezomib The serum concentration of Bortezomib can be increased when it is combined with Capmatinib. Bosentan The serum concentration of Capmatinib can be decreased when it is combined with Bosentan. Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Capmatinib. Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Capmatinib. Brigatinib The serum concentration of Capmatinib can be decreased when it is combined with Brigatinib. Bromazepam The metabolism of Bromazepam can be decreased when combined with Capmatinib. Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with Capmatinib. Budesonide The serum concentration of Capmatinib can be decreased when it is combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Butacaine. Butalbital The serum concentration of Capmatinib can be decreased when it is combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Butamben. Cabazitaxel The serum concentration of Cabazitaxel can be increased when it is combined with Capmatinib. Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Capmatinib. Caffeine The metabolism of Caffeine can be decreased when combined with Capmatinib. Calcitriol The serum concentration of Capmatinib can be decreased when it is combined with Calcitriol. Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Capmatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Capsaicin. Carbamazepine The serum concentration of Capmatinib can be decreased when it is combined with Carbamazepine. Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Capmatinib. Carfilzomib The serum concentration of Carfilzomib can be increased when it is combined with Capmatinib. Carmustine The metabolism of Carmustine can be decreased when combined with Capmatinib. Carvedilol The metabolism of Carvedilol can be decreased when combined with Capmatinib. Cefradine The serum concentration of Capmatinib can be decreased when it is combined with Cefradine. Celecoxib The serum concentration of Celecoxib can be increased when it is combined with Capmatinib. Cenobamate The serum concentration of Capmatinib can be decreased when it is combined with Cenobamate. Cephalexin The excretion of Cephalexin can be decreased when combined with Capmatinib. Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Capmatinib. Cerivastatin The serum concentration of Capmatinib can be decreased when it is combined with Cerivastatin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Chloroprocaine. Chlorphenesin The serum concentration of Capmatinib can be decreased when it is combined with Chlorphenesin. Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Capmatinib. Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Capmatinib. Cilostazol The metabolism of Cilostazol can be decreased when combined with Capmatinib. Cimetidine The serum concentration of Capmatinib can be increased when it is combined with Cimetidine. Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Capmatinib. Cinchocaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Cinchocaine. Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Capmatinib. Ciprofloxacin The serum concentration of Capmatinib can be increased when it is combined with Ciprofloxacin. Cladribine The serum concentration of Cladribine can be increased when it is combined with Capmatinib. Clarithromycin The serum concentration of Capmatinib can be increased when it is combined with Clarithromycin. Clevidipine The serum concentration of Capmatinib can be decreased when it is combined with Clevidipine. Clobazam The serum concentration of Capmatinib can be decreased when it is combined with Clobazam. Clofarabine The serum concentration of Clofarabine can be increased when it is combined with Capmatinib. Clofazimine The serum concentration of Capmatinib can be increased when it is combined with Clofazimine. Clofibrate The serum concentration of Capmatinib can be decreased when it is combined with Clofibrate. Clomifene The serum concentration of Clomifene can be increased when it is combined with Capmatinib. Clomipramine The serum concentration of Clomipramine can be increased when it is combined with Capmatinib. Clonidine The serum concentration of Clonidine can be increased when it is combined with Capmatinib. Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Capmatinib. Clotrimazole The serum concentration of Capmatinib can be decreased when it is combined with Clotrimazole. Clozapine The serum concentration of Capmatinib can be decreased when it is combined with Clozapine. Cobicistat The serum concentration of Capmatinib can be increased when it is combined with Cobicistat. Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Capmatinib. Cocaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Cocaine. Colchicine The serum concentration of Colchicine can be increased when it is combined with Capmatinib. Conivaptan The metabolism of Capmatinib can be decreased when combined with Conivaptan. Conjugated estrogens The serum concentration of Conjugated estrogens can be increased when it is combined with Capmatinib. Copanlisib The serum concentration of Copanlisib can be increased when it is combined with Capmatinib. Corticotropin The serum concentration of Capmatinib can be decreased when it is combined with Corticotropin. Crizotinib The serum concentration of Capmatinib can be increased when it is combined with Crizotinib. Curcumin The metabolism of Capmatinib can be decreased when combined with Curcumin. Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Capmatinib. Cyclophosphamide The serum concentration of Capmatinib can be decreased when it is combined with Cyclophosphamide. Cyclosporine The serum concentration of Cyclosporine can be increased when it is combined with Capmatinib. Dabigatran etexilate The serum concentration of Dabigatran etexilate can be increased when it is combined with Capmatinib. Dabrafenib The serum concentration of Capmatinib can be decreased when it is combined with Dabrafenib. Dacarbazine The serum concentration of Dacarbazine can be increased when it is combined with Capmatinib. Dacomitinib The serum concentration of Dacomitinib can be increased when it is combined with Capmatinib. Dactinomycin The serum concentration of Dactinomycin can be increased when it is combined with Capmatinib. Danazol The metabolism of Capmatinib can be decreased when combined with Danazol. Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Capmatinib. Daptomycin The serum concentration of Daptomycin can be increased when it is combined with Capmatinib. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Capmatinib. Darolutamide The serum concentration of Darolutamide can be increased when it is combined with Capmatinib. Darunavir The metabolism of Capmatinib can be decreased when combined with Darunavir. Dasabuvir The serum concentration of Dasabuvir can be increased when it is combined with Capmatinib. Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Capmatinib. Daunorubicin The serum concentration of Capmatinib can be decreased when it is combined with Daunorubicin. Deferasirox The serum concentration of Capmatinib can be decreased when it is combined with Deferasirox. Delafloxacin The serum concentration of Capmatinib can be decreased when it is combined with Delafloxacin. Delavirdine The metabolism of Capmatinib can be decreased when combined with Delavirdine. Desonide The serum concentration of Capmatinib can be decreased when it is combined with Desonide. Desvenlafaxine The metabolism of Capmatinib can be decreased when combined with Desvenlafaxine. Dexamethasone The serum concentration of Capmatinib can be decreased when it is combined with Dexamethasone. Dexamethasone acetate The serum concentration of Capmatinib can be decreased when it is combined with Dexamethasone acetate. Dexfenfluramine The metabolism of Dexfenfluramine can be decreased when combined with Capmatinib. Diclofenac The metabolism of Diclofenac can be decreased when combined with Capmatinib. Dicloxacillin The serum concentration of Capmatinib can be decreased when it is combined with Dicloxacillin. Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Capmatinib. Digoxin The serum concentration of Digoxin can be increased when it is combined with Capmatinib. Dihydralazine The metabolism of Dihydralazine can be decreased when combined with Capmatinib. Diltiazem The serum concentration of Capmatinib can be increased when it is combined with Diltiazem. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Diphenhydramine. Disopyramide The metabolism of Disopyramide can be decreased when combined with Capmatinib. Dolutegravir The serum concentration of Dolutegravir can be increased when it is combined with Capmatinib. Domperidone The metabolism of Domperidone can be decreased when combined with Capmatinib. Donepezil The serum concentration of Donepezil can be increased when it is combined with Capmatinib. Doxepin The metabolism of Doxepin can be decreased when combined with Capmatinib. Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Capmatinib. Dronedarone The metabolism of Capmatinib can be decreased when combined with Dronedarone. Duvelisib The serum concentration of Duvelisib can be increased when it is combined with Capmatinib. Dyclonine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Dyclonine. Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Capmatinib. Efavirenz The serum concentration of Capmatinib can be decreased when it is combined with Efavirenz. Elagolix The serum concentration of Capmatinib can be decreased when it is combined with Elagolix. Elbasvir The serum concentration of Elbasvir can be increased when it is combined with Capmatinib. Eletriptan The serum concentration of Capmatinib can be decreased when it is combined with Eletriptan. Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Capmatinib. Elvitegravir The metabolism of Capmatinib can be decreased when combined with Elvitegravir. Emtricitabine The excretion of Emtricitabine can be decreased when combined with Capmatinib. Enasidenib The serum concentration of Capmatinib can be decreased when it is combined with Enasidenib. Enfortumab vedotin The serum concentration of Enfortumab vedotin can be increased when it is combined with Capmatinib. Entecavir The metabolism of Entecavir can be decreased when combined with Capmatinib. Enzalutamide The serum concentration of Capmatinib can be decreased when it is combined with Enzalutamide. Ergotamine The metabolism of Capmatinib can be decreased when combined with Ergotamine. Erlotinib The serum concentration of Erlotinib can be increased when it is combined with Capmatinib. Ertugliflozin The serum concentration of Ertugliflozin can be increased when it is combined with Capmatinib. Erythromycin The serum concentration of Capmatinib can be increased when it is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Capmatinib. Esketamine The serum concentration of Capmatinib can be decreased when it is combined with Esketamine. Eslicarbazepine The serum concentration of Capmatinib can be decreased when it is combined with Eslicarbazepine. Eslicarbazepine acetate The serum concentration of Capmatinib can be decreased when it is combined with Eslicarbazepine acetate. Estradiol The metabolism of Estradiol can be decreased when combined with Capmatinib. Estradiol acetate The serum concentration of Capmatinib can be decreased when it is combined with Estradiol acetate. Estradiol benzoate The serum concentration of Capmatinib can be decreased when it is combined with Estradiol benzoate. Estradiol cypionate The serum concentration of Capmatinib can be decreased when it is combined with Estradiol cypionate. Estradiol dienanthate The serum concentration of Capmatinib can be decreased when it is combined with Estradiol dienanthate. Estradiol valerate The serum concentration of Capmatinib can be decreased when it is combined with Estradiol valerate. Estrone sulfate The metabolism of Estrone sulfate can be decreased when combined with Capmatinib. Ethanol The serum concentration of Capmatinib can be decreased when it is combined with Ethanol. Ethinylestradiol The metabolism of Ethinylestradiol can be decreased when combined with Capmatinib. Ethotoin The serum concentration of Capmatinib can be decreased when it is combined with Ethotoin. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Etidocaine. Etoposide The serum concentration of Capmatinib can be decreased when it is combined with Etoposide. Etoricoxib The metabolism of Etoricoxib can be decreased when combined with Capmatinib. Etravirine The serum concentration of Capmatinib can be decreased when it is combined with Etravirine. Everolimus The serum concentration of Everolimus can be increased when it is combined with Capmatinib. Ezetimibe The serum concentration of Ezetimibe can be increased when it is combined with Capmatinib. Fedratinib The serum concentration of Fedratinib can be increased when it is combined with Capmatinib. Felbamate The serum concentration of Capmatinib can be decreased when it is combined with Felbamate. Fenfluramine The metabolism of Fenfluramine can be decreased when combined with Capmatinib. Fexinidazole The serum concentration of Capmatinib can be increased when it is combined with Fexinidazole. Fexofenadine The serum concentration of Fexofenadine can be increased when it is combined with Capmatinib. Flecainide The metabolism of Flecainide can be decreased when combined with Capmatinib. Flucloxacillin The serum concentration of Capmatinib can be decreased when it is combined with Flucloxacillin. Fluconazole The metabolism of Capmatinib can be decreased when combined with Fluconazole. Flunarizine The metabolism of Flunarizine can be decreased when combined with Capmatinib. Fluocinolone acetonide The serum concentration of Capmatinib can be decreased when it is combined with Fluocinolone acetonide. Fluorouracil The serum concentration of Fluorouracil can be increased when it is combined with Capmatinib. Fluoxetine The metabolism of Fluoxetine can be decreased when combined with Capmatinib. Flutamide The metabolism of Flutamide can be decreased when combined with Capmatinib. Fluvoxamine The serum concentration of Capmatinib can be increased when it is combined with Fluvoxamine. Folic acid The serum concentration of Folic acid can be increased when it is combined with Capmatinib. Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Capmatinib. Formestane The serum concentration of Capmatinib can be decreased when it is combined with Formestane. Fosaprepitant The serum concentration of Capmatinib can be decreased when it is combined with Fosaprepitant. Fosnetupitant The metabolism of Capmatinib can be decreased when combined with Fosnetupitant. Fosphenytoin The serum concentration of Capmatinib can be decreased when it is combined with Fosphenytoin. Fostemsavir The serum concentration of Fostemsavir can be increased when it is combined with Capmatinib. Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Capmatinib. Fusidic acid The metabolism of Capmatinib can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Futibatinib can be increased when it is combined with Capmatinib. Ganciclovir The excretion of Ganciclovir can be decreased when combined with Capmatinib. Gefitinib The serum concentration of Gefitinib can be increased when it is combined with Capmatinib. Gemcitabine The serum concentration of Gemcitabine can be increased when it is combined with Capmatinib. Gilteritinib The serum concentration of Gilteritinib can be increased when it is combined with Capmatinib. Glasdegib The serum concentration of Glasdegib can be increased when it is combined with Capmatinib. Glecaprevir The serum concentration of Capmatinib can be increased when it is combined with Glecaprevir. Glyburide The serum concentration of Glyburide can be increased when it is combined with Capmatinib. Glycerol phenylbutyrate The serum concentration of Capmatinib can be decreased when it is combined with Glycerol phenylbutyrate. Grapefruit The serum concentration of Capmatinib can be increased when it is combined with Grapefruit. Grazoprevir The serum concentration of Grazoprevir can be increased when it is combined with Capmatinib. Grepafloxacin The metabolism of Grepafloxacin can be decreased when combined with Capmatinib. Griseofulvin The serum concentration of Capmatinib can be decreased when it is combined with Griseofulvin. Guanabenz The metabolism of Guanabenz can be decreased when combined with Capmatinib. Guanidine The excretion of Guanidine can be decreased when combined with Capmatinib. Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Capmatinib. Hydrocortamate The serum concentration of Capmatinib can be decreased when it is combined with Hydrocortamate. Hydrocortisone The serum concentration of Capmatinib can be decreased when it is combined with Hydrocortisone. Hydrocortisone acetate The serum concentration of Capmatinib can be decreased when it is combined with Hydrocortisone acetate. Hydrocortisone butyrate The serum concentration of Capmatinib can be decreased when it is combined with Hydrocortisone butyrate. Hydrocortisone probutate The serum concentration of Capmatinib can be decreased when it is combined with Hydrocortisone probutate. Hydrocortisone succinate The serum concentration of Capmatinib can be decreased when it is combined with Hydrocortisone succinate. Hydrocortisone valerate The serum concentration of Capmatinib can be decreased when it is combined with Hydrocortisone valerate. Idelalisib The serum concentration of Capmatinib can be increased when it is combined with Idelalisib. Ifosfamide The serum concentration of Capmatinib can be decreased when it is combined with Ifosfamide. Imatinib The serum concentration of Imatinib can be increased when it is combined with Capmatinib. Imipramine The serum concentration of Imipramine can be increased when it is combined with Capmatinib. Indacaterol The serum concentration of Indacaterol can be increased when it is combined with Capmatinib. Indinavir The serum concentration of Capmatinib can be increased when it is combined with Indinavir. Inotuzumab ozogamicin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Capmatinib. Irinotecan The serum concentration of Irinotecan can be increased when it is combined with Capmatinib. Isavuconazole The serum concentration of Capmatinib can be decreased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Capmatinib can be decreased when it is combined with Isavuconazonium. Isoniazid The metabolism of Capmatinib can be decreased when combined with Isoniazid. Isradipine The metabolism of Capmatinib can be decreased when combined with Isradipine. Istradefylline The metabolism of Istradefylline can be decreased when combined with Capmatinib. Itraconazole The serum concentration of Capmatinib can be increased when it is combined with Itraconazole. Ivermectin The serum concentration of Ivermectin can be increased when it is combined with Capmatinib. Ivosidenib The serum concentration of Capmatinib can be decreased when it is combined with Ivosidenib. Ketamine The serum concentration of Capmatinib can be decreased when it is combined with Ketamine. Ketoconazole The serum concentration of Capmatinib can be increased when it is combined with Ketoconazole. Lamivudine The serum concentration of Lamivudine can be increased when it is combined with Capmatinib. Lansoprazole The serum concentration of Capmatinib can be decreased when it is combined with Lansoprazole. Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Capmatinib. Lasmiditan The serum concentration of Lasmiditan can be increased when it is combined with Capmatinib. Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Capmatinib. Lefamulin Capmatinib may decrease the excretion rate of Lefamulin which could result in a higher serum level. Leflunomide The serum concentration of Leflunomide can be increased when it is combined with Capmatinib. Lemborexant The serum concentration of Lemborexant can be increased when it is combined with Capmatinib. Lenvatinib The serum concentration of Lenvatinib can be increased when it is combined with Capmatinib. Lesinurad The serum concentration of Capmatinib can be decreased when it is combined with Lesinurad. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Levobupivacaine. Levofloxacin The excretion of Levofloxacin can be decreased when combined with Capmatinib. Levoketoconazole The serum concentration of Capmatinib can be increased when it is combined with Levoketoconazole. Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Capmatinib. Lidocaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Lidocaine. Linagliptin The metabolism of Capmatinib can be decreased when combined with Linagliptin. Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Capmatinib. Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Capmatinib. Lofexidine The metabolism of Lofexidine can be decreased when combined with Capmatinib. Lomefloxacin The metabolism of Lomefloxacin can be decreased when combined with Capmatinib. Lonafarnib The metabolism of Capmatinib can be decreased when combined with Lonafarnib. Loncastuximab tesirine The serum concentration of Loncastuximab tesirine can be increased when it is combined with Capmatinib. Loperamide The excretion of Loperamide can be decreased when combined with Capmatinib. Lopinavir The serum concentration of Capmatinib can be increased when it is combined with Lopinavir. Lorcaserin The metabolism of Lorcaserin can be decreased when combined with Capmatinib. Lorlatinib The serum concentration of Capmatinib can be decreased when it is combined with Lorlatinib. Lovastatin The metabolism of Capmatinib can be decreased when combined with Lovastatin. Lumacaftor The serum concentration of Capmatinib can be decreased when it is combined with Lumacaftor. Lusutrombopag The serum concentration of Lusutrombopag can be increased when it is combined with Capmatinib. Mannitol The serum concentration of Mannitol can be increased when it is combined with Capmatinib. Maprotiline The metabolism of Maprotiline can be decreased when combined with Capmatinib. Mavacamten The serum concentration of Capmatinib can be decreased when it is combined with Mavacamten. Medroxyprogesterone The serum concentration of Capmatinib can be decreased when it is combined with Medroxyprogesterone acetate. Mefenamic acid The metabolism of Mefenamic acid can be decreased when combined with Capmatinib. Mefloquine The serum concentration of Mefloquine can be increased when it is combined with Capmatinib. Melatonin The metabolism of Melatonin can be decreased when combined with Capmatinib. Meloxicam The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Meloxicam. Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Capmatinib. Mepivacaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Mepivacaine. Metformin The excretion of Metformin can be decreased when combined with Capmatinib. Methadone The serum concentration of Capmatinib can be increased when it is combined with Methadone. Methimazole The metabolism of Capmatinib can be decreased when combined with Methimazole. Methylprednisolone The serum concentration of Capmatinib can be decreased when it is combined with Methylprednisolone. Metoclopramide The metabolism of Metoclopramide can be decreased when combined with Capmatinib. Metreleptin The metabolism of Capmatinib can be increased when combined with Metreleptin. Metyrapone The serum concentration of Capmatinib can be decreased when it is combined with Metyrapone. Mexiletine The metabolism of Mexiletine can be decreased when combined with Capmatinib. Mianserin The metabolism of Mianserin can be decreased when combined with Capmatinib. Miconazole The metabolism of Capmatinib can be decreased when combined with Miconazole. Midostaurin The serum concentration of Capmatinib can be decreased when it is combined with Midostaurin. Mifepristone The serum concentration of Capmatinib can be decreased when it is combined with Mifepristone. Milnacipran The metabolism of Capmatinib can be decreased when combined with Milnacipran. Mirabegron The serum concentration of Mirabegron can be increased when it is combined with Capmatinib. Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Capmatinib. Mitotane The serum concentration of Capmatinib can be decreased when it is combined with Mitotane. Mitoxantrone The serum concentration of Mitoxantrone can be increased when it is combined with Capmatinib. Modafinil The serum concentration of Capmatinib can be decreased when it is combined with Modafinil. Morphine The serum concentration of Morphine can be increased when it is combined with Capmatinib. Mycophenolate mofetil The serum concentration of Mycophenolate mofetil can be increased when it is combined with Capmatinib. Nabumetone The metabolism of Nabumetone can be decreased when combined with Capmatinib. Nadolol The excretion of Nadolol can be decreased when combined with Capmatinib. Nafcillin The serum concentration of Capmatinib can be decreased when it is combined with Nafcillin. Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Capmatinib. Naloxone The metabolism of Capmatinib can be decreased when combined with Naloxone. Naproxen The metabolism of Naproxen can be decreased when combined with Capmatinib. Nefazodone The serum concentration of Capmatinib can be increased when it is combined with Nefazodone. Nelfinavir The serum concentration of Capmatinib can be increased when it is combined with Nelfinavir. Netupitant The metabolism of Capmatinib can be decreased when combined with Netupitant. Nicardipine The serum concentration of Capmatinib can be increased when it is combined with Nicardipine. Nifedipine The serum concentration of Capmatinib can be decreased when it is combined with Nifedipine. Nilotinib The serum concentration of Nilotinib can be increased when it is combined with Capmatinib. Nilvadipine The metabolism of Capmatinib can be decreased when combined with Nilvadipine. Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Capmatinib. Nitrofurantoin The serum concentration of Nitrofurantoin can be increased when it is combined with Capmatinib. Norgestimate The serum concentration of Capmatinib can be decreased when it is combined with Norgestimate. Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Capmatinib. Olanzapine The metabolism of Olanzapine can be decreased when combined with Capmatinib. Omadacycline The serum concentration of Omadacycline can be increased when it is combined with Capmatinib. Ombitasvir The serum concentration of Ombitasvir can be increased when it is combined with Capmatinib. Omeprazole The serum concentration of Capmatinib can be decreased when it is combined with Omeprazole. Ondansetron The metabolism of Ondansetron can be decreased when combined with Capmatinib. Oritavancin The serum concentration of Capmatinib can be decreased when it is combined with Oritavancin. Osilodrostat The serum concentration of Capmatinib can be increased when it is combined with Osilodrostat. Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Capmatinib. Oxaliplatin The serum concentration of Oxaliplatin can be increased when it is combined with Capmatinib. Oxcarbazepine The serum concentration of Capmatinib can be decreased when it is combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Oxetacaine. Oxiconazole The serum concentration of Capmatinib can be decreased when it is combined with Oxiconazole. Oxtriphylline The metabolism of Oxtriphylline can be decreased when combined with Capmatinib. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Oxybuprocaine. Ozanimod Capmatinib may decrease the excretion rate of Ozanimod which could result in a higher serum level. Paclitaxel The serum concentration of Capmatinib can be decreased when it is combined with Paclitaxel. Palbociclib The serum concentration of Palbociclib can be increased when it is combined with Capmatinib. Paliperidone The serum concentration of Paliperidone can be increased when it is combined with Capmatinib. Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Capmatinib. Parathyroid hormone The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Capmatinib. Paritaprevir The serum concentration of Paritaprevir can be increased when it is combined with Capmatinib. Paroxetine The serum concentration of Capmatinib can be increased when it is combined with Paroxetine. Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Capmatinib. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Capmatinib. Pegvisomant The serum concentration of Capmatinib can be decreased when it is combined with Pegvisomant. Pemetrexed The metabolism of Pemetrexed can be decreased when combined with Capmatinib. Penciclovir The metabolism of Penciclovir can be decreased when combined with Capmatinib. Pentobarbital The serum concentration of Capmatinib can be decreased when it is combined with Pentobarbital. Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Capmatinib. Perampanel The serum concentration of Capmatinib can be decreased when it is combined with Perampanel. Perphenazine The metabolism of Perphenazine can be decreased when combined with Capmatinib. Phenobarbital The serum concentration of Capmatinib can be decreased when it is combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Phenol. Phenylbutazone The serum concentration of Capmatinib can be decreased when it is combined with Phenylbutazone. Phenytoin The serum concentration of Capmatinib can be decreased when it is combined with Phenytoin. Pibrentasvir The serum concentration of Pibrentasvir can be increased when it is combined with Capmatinib. Pimozide The serum concentration of Pimozide can be increased when it is combined with Capmatinib. Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Capmatinib. Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Capmatinib. Pitolisant The serum concentration of Capmatinib can be decreased when it is combined with Pitolisant. Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Capmatinib. Ponatinib The serum concentration of Ponatinib can be increased when it is combined with Capmatinib. Posaconazole The metabolism of Capmatinib can be decreased when combined with Posaconazole. Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Capmatinib. Potassium perchlorate The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Capmatinib. Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with Capmatinib. Pralsetinib The serum concentration of Capmatinib can be decreased when it is combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Pramocaine. Prasterone The serum concentration of Capmatinib can be increased when it is combined with Prasterone. Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Capmatinib. Praziquantel The metabolism of Praziquantel can be decreased when combined with Capmatinib. Prazosin The serum concentration of Prazosin can be increased when it is combined with Capmatinib. Prednicarbate The serum concentration of Capmatinib can be decreased when it is combined with Prednicarbate. Prednisolone The serum concentration of Capmatinib can be decreased when it is combined with Prednisolone. Prednisolone phosphate The serum concentration of Prednisolone phosphate can be increased when it is combined with Capmatinib. Prilocaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Prilocaine. Primaquine The metabolism of Capmatinib can be decreased when combined with Primaquine. Primidone The serum concentration of Capmatinib can be decreased when it is combined with Primidone. Probenecid The serum concentration of Capmatinib can be decreased when it is combined with Probenecid. Procainamide The serum concentration of Procainamide can be increased when it is combined with Capmatinib. Procaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Procaine. Progesterone The serum concentration of Capmatinib can be decreased when it is combined with Progesterone. Promazine The metabolism of Promazine can be decreased when combined with Capmatinib. Propafenone The metabolism of Propafenone can be decreased when combined with Capmatinib. Proparacaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Propoxycaine. Propranolol The metabolism of Propranolol can be decreased when combined with Capmatinib. Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Capmatinib. Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Capmatinib. Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Capmatinib. Quinidine The serum concentration of Capmatinib can be increased when it is combined with Quinidine. Quinine The serum concentration of Capmatinib can be decreased when it is combined with Quinine. Raloxifene The serum concentration of Raloxifene can be increased when it is combined with Capmatinib. Ramelteon The metabolism of Ramelteon can be decreased when combined with Capmatinib. Ranitidine The metabolism of Ranitidine can be decreased when combined with Capmatinib. Ranolazine The serum concentration of Capmatinib can be increased when it is combined with Ranolazine. Rasagiline The metabolism of Rasagiline can be decreased when combined with Capmatinib. Regorafenib The serum concentration of Regorafenib can be increased when it is combined with Capmatinib. Relebactam The excretion of Relebactam can be decreased when combined with Capmatinib. Relugolix The serum concentration of Relugolix can be increased when it is combined with Capmatinib. Remdesivir The serum concentration of Capmatinib can be increased when it is combined with Remdesivir. Reserpine The serum concentration of Capmatinib can be decreased when it is combined with Reserpine. Revefenacin The serum concentration of Revefenacin can be increased when it is combined with Capmatinib. Ribociclib The metabolism of Capmatinib can be decreased when combined with Ribociclib. Rifabutin The serum concentration of Capmatinib can be decreased when it is combined with Rifabutin. Rifampicin The serum concentration of Capmatinib can be decreased when it is combined with Rifampicin. Rifamycin The serum concentration of Capmatinib can be decreased when it is combined with Rifamycin. Rifapentine The serum concentration of Capmatinib can be decreased when it is combined with Rifapentine. Rifaximin The serum concentration of Capmatinib can be decreased when it is combined with Rifaximin. Riluzole The serum concentration of Riluzole can be increased when it is combined with Capmatinib. Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Capmatinib. Riociguat The serum concentration of Riociguat can be increased when it is combined with Capmatinib. Ripretinib The serum concentration of Ripretinib can be increased when it is combined with Capmatinib. Ritonavir The serum concentration of Capmatinib can be increased when it is combined with Ritonavir. Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Capmatinib. Rofecoxib The serum concentration of Capmatinib can be decreased when it is combined with Rofecoxib. Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Capmatinib. Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Capmatinib. Ropinirole The risk or severity of adverse effects can be increased when Capmatinib is combined with Ropinirole. Ropivacaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Ropivacaine. Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Capmatinib. Rucaparib The serum concentration of Rucaparib can be increased when it is combined with Capmatinib. Rufinamide The serum concentration of Capmatinib can be decreased when it is combined with Rufinamide. Salmon calcitonin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Capmatinib. Saquinavir The metabolism of Capmatinib can be decreased when combined with Saquinavir. Sarilumab The serum concentration of Capmatinib can be decreased when it is combined with Sarilumab. Satralizumab The serum concentration of Capmatinib can be decreased when it is combined with Satralizumab. Secobarbital The serum concentration of Capmatinib can be decreased when it is combined with Secobarbital. Selegiline The metabolism of Selegiline can be decreased when combined with Capmatinib. Selexipag The serum concentration of Selexipag can be increased when it is combined with Capmatinib. Selpercatinib The serum concentration of Capmatinib can be increased when it is combined with Selpercatinib. Selumetinib The serum concentration of Selumetinib can be increased when it is combined with Capmatinib. Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Capmatinib. Silodosin The excretion of Silodosin can be decreased when combined with Capmatinib. Siltuximab The serum concentration of Capmatinib can be decreased when it is combined with Siltuximab. Simeprevir The serum concentration of Simeprevir can be increased when it is combined with Capmatinib. Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Capmatinib. Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Capmatinib. Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Capmatinib. Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Capmatinib. Solriamfetol The excretion of Solriamfetol can be decreased when combined with Capmatinib. Somatrogon The metabolism of Capmatinib can be increased when combined with Somatrogon. Sorafenib The serum concentration of Sorafenib can be increased when it is combined with Capmatinib. Sotorasib The serum concentration of Capmatinib can be decreased when it is combined with Sotorasib. St. John's Wort The serum concentration of Capmatinib can be decreased when it is combined with St. John's Wort. Stiripentol The serum concentration of Capmatinib can be increased when it is combined with Stiripentol. Sulfasalazine The serum concentration of Sulfasalazine can be increased when it is combined with Capmatinib. Sulfinpyrazone The serum concentration of Capmatinib can be decreased when it is combined with Sulfinpyrazone. Sumatriptan The serum concentration of Sumatriptan can be increased when it is combined with Capmatinib. Tacrine The metabolism of Tacrine can be decreased when combined with Capmatinib. Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Capmatinib. Tamoxifen The serum concentration of Capmatinib can be decreased when it is combined with Tamoxifen. Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Capmatinib. Tazemetostat The serum concentration of Tazemetostat can be increased when it is combined with Capmatinib. Technetium Tc The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Capmatinib. Tegafur The serum concentration of Tegafur can be increased when it is combined with Capmatinib. Tegaserod The serum concentration of Tegaserod can be increased when it is combined with Capmatinib. Telaprevir The metabolism of Capmatinib can be decreased when combined with Telaprevir. Telithromycin The metabolism of Capmatinib can be decreased when combined with Telithromycin. Telotristat ethyl The serum concentration of Capmatinib can be decreased when it is combined with Telotristat ethyl. Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Capmatinib. Teniposide The serum concentration of Teniposide can be increased when it is combined with Capmatinib. Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be increased when it is combined with Capmatinib. Tenofovir disoproxil The serum concentration of Tenofovir disoproxil can be increased when it is combined with Capmatinib. Tepotinib The serum concentration of Tepotinib can be increased when it is combined with Capmatinib. Terbinafine The serum concentration of Capmatinib can be decreased when it is combined with Terbinafine. Terfenadine The serum concentration of Capmatinib can be decreased when it is combined with Terfenadine. Teriflunomide The serum concentration of Teriflunomide can be increased when it is combined with Capmatinib. Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Capmatinib. Testosterone The serum concentration of Capmatinib can be decreased when it is combined with Testosterone. Testosterone cypionate The serum concentration of Capmatinib can be decreased when it is combined with Testosterone cypionate. Testosterone enanthate The serum concentration of Capmatinib can be decreased when it is combined with Testosterone enanthate. Testosterone The serum concentration of Capmatinib can be decreased when it is combined with Testosterone undecanoate. Tetracaine The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Tetracaine. Tezacaftor The serum concentration of Tezacaftor can be increased when it is combined with Capmatinib. Thalidomide The serum concentration of Capmatinib can be decreased when it is combined with Thalidomide. Theophylline The serum concentration of Theophylline can be increased when it is combined with Capmatinib. Thiabendazole The metabolism of Thiabendazole can be decreased when combined with Capmatinib. Thiopental The serum concentration of Capmatinib can be decreased when it is combined with Thiopental. Thiothixene The metabolism of Thiothixene can be decreased when combined with Capmatinib. Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Capmatinib. Thyrotropin alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Capmatinib. Ticagrelor The serum concentration of Ticagrelor can be increased when it is combined with Capmatinib. Tipranavir The metabolism of Capmatinib can be decreased when combined with Tipranavir. Tivozanib The serum concentration of Tivozanib can be increased when it is combined with Capmatinib. Tizanidine The serum concentration of Tizanidine can be increased when it is combined with Capmatinib. Tocainide The metabolism of Tocainide can be decreased when combined with Capmatinib. Tocilizumab The serum concentration of Capmatinib can be decreased when it is combined with Tocilizumab. Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Capmatinib. Topiramate The serum concentration of Capmatinib can be decreased when it is combined with Topiramate. Topotecan The serum concentration of Topotecan can be increased when it is combined with Capmatinib. Toremifene The serum concentration of Toremifene can be increased when it is combined with Capmatinib. Trametinib The serum concentration of Capmatinib can be decreased when it is combined with Trametinib. Trastuzumab emtansine The serum concentration of Trastuzumab emtansine can be increased when it is combined with Capmatinib. Triamterene The metabolism of Triamterene can be decreased when combined with Capmatinib. Triclabendazole The metabolism of Triclabendazole can be decreased when combined with Capmatinib. Trifluoperazine The metabolism of Trifluoperazine can be decreased when combined with Capmatinib. Trilaciclib The serum concentration of Trilaciclib can be increased when it is combined with Capmatinib. Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Capmatinib. Troglitazone The serum concentration of Capmatinib can be decreased when it is combined with Troglitazone. Troleandomycin The serum concentration of Capmatinib can be increased when it is combined with Troleandomycin. Tucatinib The serum concentration of Capmatinib can be increased when it is combined with Tucatinib. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Capmatinib. Umeclidinium The serum concentration of Umeclidinium can be increased when it is combined with Capmatinib. Ursodeoxycholic acid The serum concentration of Capmatinib can be decreased when it is combined with Ursodeoxycholic acid. Vardenafil The serum concentration of Vardenafil can be increased when it is combined with Capmatinib. Velpatasvir The serum concentration of Velpatasvir can be increased when it is combined with Capmatinib. Vemurafenib The serum concentration of Capmatinib can be decreased when it is combined with Vemurafenib. Venetoclax The serum concentration of Venetoclax can be increased when it is combined with Capmatinib. Verapamil The serum concentration of Capmatinib can be increased when it is combined with Verapamil. Viloxazine The serum concentration of Capmatinib can be increased when it is combined with Viloxazine. Vinblastine The serum concentration of Capmatinib can be decreased when it is combined with Vinblastine. Vincristine The serum concentration of Vincristine can be increased when it is combined with Capmatinib. Vinflunine The serum concentration of Vinflunine can be increased when it is combined with Capmatinib. Voclosporin The serum concentration of Voclosporin can be increased when it is combined with Capmatinib. Voriconazole The serum concentration of Capmatinib can be increased when it is combined with Voriconazole. Voxilaprevir The serum concentration of Voxilaprevir can be increased when it is combined with Capmatinib. Warfarin The serum concentration of Warfarin can be increased when it is combined with Capmatinib. Zafirlukast The serum concentration of Capmatinib can be increased when it is combined with Zafirlukast. Zidovudine The serum concentration of Zidovudine can be increased when it is combined with Capmatinib. Zileuton The metabolism of Zileuton can be decreased when combined with Capmatinib. Zimelidine The metabolism of Capmatinib can be decreased when combined with Zimelidine. Ziprasidone The metabolism of Capmatinib can be decreased when combined with Ziprasidone. Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Capmatinib. Zolpidem The metabolism of Zolpidem can be decreased when combined with Capmatinib. Zotepine The metabolism of Zotepine can be decreased when combined with Capmatinib. Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy Based on findings from animal studies and its mechanism of action, TABRECTA can cause fetal harm when administered to a pregnant woman. There are no available data on TABRECTA use in pregnant women. Oral administration of capmatinib to pregnant rats and rabbits during the period of organogenesis resulted in malformations at maternal exposures less than the human exposure based on AUC at the 400 mg twice daily clinical dose. Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Lactation There are no data on the presence of capmatinib or its metabolites in either human or animal milk or its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with TABRECTA and for 1 week after the last dose. How should this medicine be used?

Capmatinib comes as a tablet to take by mouth. It is usually taken twice daily with or without food. Take capmatinib at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take capmatinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Swallow the tablets whole; do not split,…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   Vasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    Cholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    Imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    A thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    Propylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    Methimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    Mirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)